XENE
Xenon Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.24B
P/E Ratio
—
EPS
$-4.70
Beta
0.65
52W High
$63.95
52W Low
$28.19
50-Day MA
$56.13
200-Day MA
$45.06
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.06
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company is headquartered in Burnaby, Canada.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-328.25M |
| EBITDA | $-410.19M |
| Operating Margin | 0.00% |
| Return on Equity | -37.50% |
| Return on Assets | -24.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.27 |
| Price-to-Book | 3.91 |
| Price-to-Sales (TTM) | 727.44 |
| EV/Revenue | 649.22 |
| EV/EBITDA | 34.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $96.67M |
| Float | $90.77M |
| % Insiders | 0.12% |
| % Institutions | 107.69% |
Analyst Ratings
Consensus ($79.19 target)
3
Strong Buy17
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026